Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The word “children” may come second in their name, but Seattle Children’s Hospital is proving they truly put children first.
George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
There are many examples of how biopharma is leveraging AI and forging partnerships with companies focused on AI for drug development and clinical trials. There have been a few recent AI-based partnerships as well.
Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
The 2020 Virtual Texas Life Science Forum, sponsored by BioHouston November 10-12, showcased dozens of innovative, early stage companies seeking partners to reach the next level.
Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.